Travere (TVTX) CFO gets 75,000 options and tax-related share sale

Rhea-AI Filing Summary

Travere Therapeutics' Chief Financial Officer Christopher R. Cline reported equity compensation activity and a related share sale. On January 31, 2026, he acquired 28,130 shares of common stock for $0 upon settlement of restricted stock units and held 120,213 shares afterward.

That same day he received an employee stock option for 75,000 shares at an exercise price of $33.095, expiring on January 31, 2036, with one-fourth vesting after one year and the rest vesting in 36 monthly installments. On February 3, 2026, he sold 7,242 shares at $32.12 per share to cover tax withholding from the vested restricted stock units, leaving him with 112,971 directly owned shares; the filing notes this was a mandated “sell to cover” transaction, not a discretionary trade.

Insider Trade Summary

Net Seller: 7,242 shares ($232,613)

Net Sell 3 txns

Insider Cline Christopher R.

Role CHIEF FINANCIAL OFFICER

Sold 7,242 shs ($233K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,242	$32.12	$233K
Grant/Award	Employee stock option (right to buy)	75,000	$0.00	--
Grant/Award	Common Stock	28,130	$0.00	--

Holdings After Transaction: Common Stock — 112,971 shares (Direct); Employee stock option (right to buy) — 75,000 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cline Christopher R.

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, STE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A(1)		28,130	A	$0	120,213	D
Common Stock	02/03/2026		S(2)		7,242	D	$32.12	112,971	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$33.095	01/31/2026		A		75,000		(3)	01/31/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

2. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

3. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Travere Therapeutics (TVTX) CFO report on this Form 4?

The CFO reported RSU settlement, an option grant, and a tax-related share sale. He received 28,130 common shares at $0, a 75,000-share stock option at $33.095, and sold 7,242 shares at $32.12 to cover tax withholding obligations.

How many Travere Therapeutics (TVTX) shares does the CFO own after these transactions?

After the reported transactions, the CFO directly owns 112,971 shares of Travere common stock. This reflects RSU settlement adding 28,130 shares and a subsequent sale of 7,242 shares to satisfy tax withholding associated with the vested restricted stock units.

Was the Travere Therapeutics (TVTX) CFO’s sale of 7,242 shares a discretionary trade?

No, the 7,242-share sale was not discretionary. Footnotes explain it was a mandated “sell to cover” transaction to pay tax withholding on vested restricted stock units, executed through a brokerage firm designated under the company’s equity incentive plans.

What are the key terms of the Travere Therapeutics (TVTX) CFO’s new stock option grant?

The CFO received an option to buy 75,000 shares at $33.095 per share, expiring January 31, 2036. One-fourth vests on the first anniversary of grant, with the remaining shares vesting in 36 equal monthly installments thereafter.

What did the Travere Therapeutics (TVTX) RSU settlement provide to the CFO?

Each restricted stock unit converted into one share of common stock, giving the CFO 28,130 shares at $0 on settlement. These RSUs represent contingent rights that deliver shares upon vesting, forming part of his equity-based compensation package.

What role does the reporting person hold at Travere Therapeutics (TVTX)?

The reporting person, Christopher R. Cline, serves as Chief Financial Officer of Travere Therapeutics. The Form 4 lists him as an officer, not a director or 10% owner, and reports his direct ownership of common stock and derivative equity awards.